Podbit · The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch
Subcritical reactors operate permanently below the criticality threshold, meaning the reaction physically cannot run away. A particle accelerator provides the extra neutrons — and when you turn the accelerator off, the power stops completely. It solves the fundamental guarantee problem that has blocked nuclear regulation for 40 years.
Where this was said
At 1:11:10 · chapter starts 1:10:00
Fred didn't set out to start a nuclear company — he went looking to invest in one, figuring his expertise in navigating highly regulated industries could accelerate an existing player. What he found instead was disappointment: almost everyone in nuclear was treating it as an engineering challenge, when the real barrier is regulatory. Safe nuclear reactors have existed since the 1960s; the engineering is solved. The problem is that the anti-nuclear push of the 1980s created a regulatory environment requiring absolute guarantees under once-in-a-million-year scenarios, which traditional criticality-balanced reactors cannot provide. Fred then stumbled upon the energy amplifier concept developed by Carlo Rubbia, the Nobel laureate and former CERN director, in the late 1980s. The design operates permanently at 0.97 criticality — always below the threshold at which a chain reaction sustains itself. A particle accelerator provides the extra neutrons needed to generate power. When the accelerator turns off, the reaction stops immediately. No matter what you do to the reactor, even 10x the accelerator power, criticality cannot be reached. This removes the fundamental guarantee problem from nuclear regulation. The only active construction of such a system is in China, based on a US design abandoned after Fukushima. Fred and his wife co-founded Subcritical to fill that gap, estimating each 300-megawatt deployment at approximately $1 billion in construction cost, financed through infrastructure-style equity-and-debt structures. He predicts coal will largely disappear from the energy mix over the next decade, and sees AI-assisted mechanical design as a key enabler for accelerating Subcritical's development.
Fred Turner predicted that within 3 years, companies will spend 2-5x a developer's salary on AI model APIs, up from the current ~3.8% noted by Mark Benioff.
The widely shared claim that we have a credit card's worth of plastic in our brains may be a massive overestimate. Researchers used nitrile gloves to measure microplastics — and nitrile gloves shed microplastic particles onto the measuring device. A second paper found the original tool used was unreliable, and that we may have far less plastic than reported.
RSD isn't just hurt feelings — it's a dopamine-deficient brain with a hyperactive amygdala and a frayed connection to the prefrontal cortex. Add a surge of norepinephrine and you get chest pain, sweating, and trembling that convinces your body something catastrophic is happening.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
Ask one question of any peptide advocate: what evidence would prove this claim wrong? If every disappointing result gets attributed to wrong dose, bad supplier, wrong timing, or improper stacking, the hypothesis is not falsifiable — and a non-falsifiable claim is not a scientific claim.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.